GV20 Oncotherapy, a Cambridge, USA and Shanghai, China-based biotechnology company with expertise in novel target identification and antibody drug discovery in immuno-oncology, completion of its Series B financing.
The round, whose amount was not disclosed, was led by Coatue Management, with participation from existing investors IDG Capital, 3W Investment, Watson Capital, Linear Capital, and additional investors.
Co-founded in 2016 by Shirley Liu, a Professor at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, and Ted Xiao, a former postdoctoral fellow at Dana-Farber Cancer Institute and Harvard Medical School, GV20 Oncotherapy applies novel genomics and AI techniques to accelerate antibody drug discovery and development for cancer immunotherapy.
Proceeds from this financing will be used to advance the company’s lead antibody program into the clinic in the coming year while expanding its drug discovery portfolio against additional immune-oncology targets. The lead antibody program is directed against a novel immunotherapy target where internal pre-clinical studies have demonstrated remarkable in vivo efficacy as a single-agent as well as in combination with established immunotherapy. GV20 intends to develop select additional clinical antibody candidates through external biopharmaceutical collaborations.
FinSMEs
18/10/2021